Description
Principle of the Assay: The Human TGFBR3 ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of Human TGFBR3 in Cell Culture Supernates, Serum, Plasma. This assay employs an antibody specific for Human TGFBR3 coated on a 96-well plate. Standards and samples are pipetted into the wells and TGFBR3 present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-Human TGFBR3 antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of TGFBR3 bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.
Background: Betaglycan also known as Transforming growth factor beta receptor III (TGFBR3), is a cell- surfacechondroitin sulfate / heparan sulfate proteoglycan >300 kDa in molecular weight. Betaglycan binds to various members of the TGF-beta superfamily of ligands via its core protein, and bFGF via its heparan sulfate chains. It is not involved directly in TGF-beta signal transduction but by binding to various member of the TGF-beta superfamily at the cell surface it acts as a reservoir of ligand for TGF-beta receptors. By cDNA array and immunohistochemistry analyses, it is found that TGFBR3 expression is lost in most breast cancers examined in association with loss of heterozygosity of the TGFBR3 locus. TGFBR3 expression decreased during breast cancer progression, and low levels predicted decreased recurrence-free survival in patients. Loss of TGFBR3 through allelic imbalance is a frequent genetic event during breast cancer development that increases metastatic potential. Also, TGFBR3 can localize transformation in the heart and play an essential, nonredundant role in TGF-beta signaling